tiprankstipranks
Advertisement
Advertisement
Mesoblast reports March quarter Ryoncil sales of $30.3M
PremiumThe FlyMesoblast reports March quarter Ryoncil sales of $30.3M
23d ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
1M ago
Mesoblast Grants New Director Options Following 2025 AGM Approvals
Premium
Company Announcements
Mesoblast Grants New Director Options Following 2025 AGM Approvals
1M ago
Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
PremiumCompany AnnouncementsMesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
3M ago
Mesoblast Lifts Ryoncil Revenues, Secures Cheaper Credit and Advances Late-Stage Cell Therapy Pipeline
Premium
Company Announcements
Mesoblast Lifts Ryoncil Revenues, Secures Cheaper Credit and Advances Late-Stage Cell Therapy Pipeline
3M ago
Mesoblast Reports 84% Survival in Early Real‑World Use of Ryoncil for Pediatric SR‑aGvHD
Premium
Company Announcements
Mesoblast Reports 84% Survival in Early Real‑World Use of Ryoncil for Pediatric SR‑aGvHD
3M ago
Mesoblast Expands Share Capital After Exercise of 6.9 Million Options
PremiumCompany AnnouncementsMesoblast Expands Share Capital After Exercise of 6.9 Million Options
4M ago
Mesoblast Lapses 3 Million Unquoted Warrants, Slightly Simplifying Capital Structure
Premium
Company Announcements
Mesoblast Lapses 3 Million Unquoted Warrants, Slightly Simplifying Capital Structure
4M ago
Mesoblast chair Jane Bell to transition out of role, Philip Facchina to succeed
Premium
The Fly
Mesoblast chair Jane Bell to transition out of role, Philip Facchina to succeed
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100